Despite being relatively common and frequently severe, RA-ILD has been a neglected area of research and indeed of clinical management in RA. In recent years we finally seem to have started making some progress in this area and this momentum has continued with a several interesting abstracts at EULAR 2021. Here are four selected for review.

RheumNow faculty reporters scoured the Posters and Presentations from virtual EULAR 2021.  Several of these are novel enough to be worthy of your consideration.  Below is the list of the six most often retweeted abstracts from Day 1.

An analysis of SLE samples from SLE 1760 patients with active disease from RCTs illustrated several known and some new targets for SLE treatment (POS0351).

Combination disease modifying antirheumatic drug (DMARD) therapy may not be only for rheumatoid arthritis; combining disease modifying agents may be the path to better renal response. 

Cutaneous lupus erythematosus (CLE) consists of a wide range of dermatologic manifestations seen in people with or without systemic lupus erythematosus (SLE). CLE can be categorised into LE-specific lesions, i.e. acute CLE (ACLE), subacute CLE (SCLE) and chronic CLE (CCLE), and nonspecific LE skin lesions (e.g. vasculitis).

Patients with Sjogren’s syndrome are nearly 19 times more likely to develop lymphoma, so identifying factors that impact this risk development is a major goal in caring for this disorder. Many risk factors are established such as low C4, palpable purpura, parotid gland enlargement, and monoclonal gammopathy.